![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
HM Cherwinski, D McCarley, R Schatzman, B Devens and JT Ransom
Institute of Immunology and Biological Sciences, Syntex Discovery Research, Palo Alto, California.
Leflunomide is a novel and effective immunosuppressant that holds promise as a therapeutic agent, but the mechanism of action is unknown. Here we provide evidence that leflunomide is a general cytostatic agent for a wide range of cells. The IC50 for proliferation in transformed cell lines ranged from 2 to 16 microM. The mean IC50 for proliferation of mitogen-stimulated rat lymphocytes (86 nM) was much lower than for mouse (3.5 microM) or human (12.5 microM) lymphocytes. Initial signal transduction events (epidermal growth factor receptor-stimulated phosphotyrosine formation and phytohemagglutinin-stimulated Ca++ mobilization) were unaffected by antiproliferative concentrations of leflunomide. Leflunomide was equally as effective against mitogenic stimuli that bypass initial signaling events as it was against surface receptor-mediated mitogens. Leflunomide was fully potent when added 8 hr after the mitogenic stimulus. Cytokine dependent T-cell growth also was blocked by leflunomide. Leflunomide caused only partial reductions of autocrine cytokine production or cytokine receptor expression. Leflunomide blocked completely the progression of rat lymphocytes beyond early S-phase of cell cycle and inhibited entry of human T-cells into the G2 and M-phases without causing cell death. Inhibition of proliferation could not be reversed by purine nucleosides. The results suggest that leflunomide's mechanism of action differs from that of other immunosuppressive agents such as corticosteroids, Cyclosporine A, rapamycin or mycophenolic acid.
This article has been cited by other articles:
|
|
 |
|
  N. Sawamukai, K. Saito, K. Yamaoka, S. Nakayamada, C. Ra, and Y. Tanaka Leflunomide Inhibits PDK1/Akt Pathway and Induces Apoptosis of Human Mast Cells J. Immunol., November 15, 2007; 179(10): 6479 - 6484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cefle Leflunomide and Azathioprine Combination in Refractory Adult-Onset Still's Disease Ann. Pharmacother., April 1, 2005; 39(4): 764 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F C Breedveld and J-M Dayer Leflunomide: mode of action in the treatment of rheumatoid arthritis Ann Rheum Dis, November 1, 2000; 59(11): 841 - 849. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Ruckemann, L. D. Fairbanks, E. A. Carrey, C. M. Hawrylowicz, D. F. Richards, B. Kirschbaum, and H. A. Simmonds Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogen-stimulated T-lymphocytes from Healthy Humans J. Biol. Chem., August 21, 1998; 273(34): 21682 - 21691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Siemasko, A. S-F. Chong, H.-M. Jack, H. Gong, J. W. Williams, and A. Finnegan Inhibition of JAK3 and STAT6 Tyrosine Phosphorylation by the Immunosuppressive Drug Leflunomide Leads to a Block in IgG1 Production J. Immunol., February 15, 1998; 160(4): 1581 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Xu, J. W. Williams, J. Shen, H. Gong, D.-P. Yin, L. Blinder, R. T. Elder, H. Sankary, A. Finnegan, and A. S.-F. Chong In Vitro and In Vivo Mechanisms of Action of the Antiproliferative and Immunosuppressive Agent, Brequinar Sodium J. Immunol., January 15, 1998; 160(2): 846 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Curnock, P. A. Robson, C. M. Yea, D. Moss, S. Gadher, T. A. Thomson, R. Westwood, E. Ruuth, and R. A. Williamson Potencies of Leflunomide and HR325 as Inhibitors of Prostaglandin Endoperoxide H Synthase-1 and -2: Comparison with Nonsteroidal Anti-Inflammatory Drugs J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 339 - 347. [Abstract] [Full Text]
|
|
|
|
|
|
R. A. Williamson, C. M. Yea, P. A. Robson, A. P. Curnock, S. Gadher, A. B. Hambleton, K. Woodward, J.-M. Bruneau, P. Hambleton, D. Moss, et al. Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory Compound J. Biol. Chem., September 22, 1995; 270(38): 22467 - 22472. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
